x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

science life sciences

All Episodes

00:08:29

ASCO 2025: Novocure today announced positive overall...

BiotechTV - News ·

2025/05/31

CEO Ashley Cordova describes the idea behind tumor treating fields, and walks us through today's pancreatic cancer data. Plus, how the company's launches are going in brain and lung cancers, and preparing to file in pancreatic later this year.

en-us

00:15:21

ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day...

BiotechTV - News ·

2025/05/31

He discusses the result of the ASCENT-04 study, which was in combination with Keytruda in PD-L1+ patients, and highlights data forthcoming at a future meeting for ASCENT-03 in PD-L1 negative patients. Plus, a brain cancer cell therapy program, Gilead's partnership with Arcus on TIGIT, and the company's deal appetite.

en-us

00:09:58

ASCO 2025: Instil Bio CEO Bronson Crouch discusses...

BiotechTV - News ·

2025/05/30

He offers what he believes are learnings from this morning's data, and describes the data Instil's partner ImmuneOnco has derived for their asset to date. Plus, plans for future data later this year and getting a U.S. study up and running.

en-us

00:19:01

Pfizer Chairman & CEO Dr. Albert Bourla discusses the...

BiotechTV - News ·

2025/05/30

Dr. Bourla looks back on Pfizers $43B acquisition of Seagen and the company's more recent license of a VEGF x PD1 bispecific. He highlights ASCO data for BRAFTOVI, vepdegestrant, and XTANDI. Plus, his thoughts on the hot button issues of China biotech and biopharma's public reputation.

en-us

00:07:27

Piper Sandler Senior Analyst David Amsellem reacts to...

BiotechTV - News ·

2025/05/29

He gives his thoughts on the competitiveness of Teva's TL1A, and highlights other pipeline programs that biotech investors might look at. Plus, how the company is doing transitioning its investor base from generic drug focused investors to biotech.

en-us

00:08:11

At Teva's Innovation & Strategy Day in New York...

BiotechTV - News ·

2025/05/29

He highlights Teva's improved financial position, its commercial prowess, and the pipeline assets to watch, including a TL1A that biotech investors have been watching closely.

en-us

00:15:56

Previewing top breast cancer and antibody-drug...

BiotechTV - News ·

2025/05/28

He describes key presentations for Enhertu, TRODELVY, immunotherapy medicines, and a couple key biomarkers to watch.

en-us

00:06:12

RBC Global Healthcare Conference: Desk Strategist...

BiotechTV - News ·

2025/05/21

He describes how policy, macro, and events have been affecting trading in biotech stocks lately. Plus, his thoughts on the pull back of generalists from the sector.

en-us

00:09:09

RBC Global Healthcare Conference: Senior Biotech...

BiotechTV - News ·

2025/05/21

He shares his overall thoughts on the biotech market, and discusses gene therapies, RNA editing, and cell therapy.

en-us

00:10:14

RBC Global Healthcare Conference: Korro Bio entered...

BiotechTV - News ·

2025/05/21

CEO Ram Aiyar describes Korro's 'OPERA' platform and explains why he thinks it is differentiated from others in the field. He previews the first data announcement that will happen later this year and discusses other work, including with the company's partner Novo Nordisk.

en-us

00:11:34

RBC Global Healthcare Conference: With a phase 3 for...

BiotechTV - News ·

2025/05/21

CEO Sanjay Shukla describes the science behind tRNA synthetase biology and how aTyr is leveraging it against inflammatory and fibrotic diseases, especially pulmonary disease. He sets up the phase 3 for Efzofitimod in pulmonary sarcoidosis, and also pending data in systemic sclerosis.

en-us

00:15:15

RBC Global Healthcare Conference: Ocular...

BiotechTV - News ·

2025/05/21

He describes where he sees AXPAXLI fitting into the treatment paradigm, and shares an update on the SOL-1 and SOL-R studies - including the rationale for recent changes to them. Plus an update on the NPDR indication.

en-us

00:09:15

RBC Global Healthcare Conference: RBC's Brian...

BiotechTV - News ·

2025/05/21

He describes some of the discussions he is having at the conference, discusses the difference between how large companies he covers are handling volatility vs smaller ones, and offers his take on the prospects for M&A.

en-us

00:17:04

RBC Global Healthcare Conference: Ahead of an...

BiotechTV - News ·

2025/05/21

He describes the science behind Cidara's Cloudbreak Drug-Fc conjugates, which might have uniform efficacy regardless of how the flu changes each season. Plus, a preview of next month's readout, and how FDA discussions around this have been.

en-us

00:09:34

Stevenage, UK based TessellateBio recently signed a...

BiotechTV - News ·

2025/05/20

CEO Andree Blaukat describes TessellateBio's focus on synthetic lethality and the science behind this lead area they have partnered with Boehring Ingelheim on, which seeks to interrupt some cancers' ability to harness telomeres to continuously replicate. The deal is potentially work in excess of €500 million. Plus addition programs, including one targeting SKP2.

en-us

00:14:21

Cambridge, UK based Maxion Therapeutics raised a $72M...

BiotechTV - News ·

2025/05/16

CEO Arndt Schottelius describes the rationale behind the KnotBody platform and the company's future plans to develop them against things like inflammatory diseases such as atopic dermatitis and inflammatory bowel disease.

en-us

00:08:34

ASGCT 2025: HuidaGene presented preclinical and early...

BiotechTV - News ·

2025/05/16

CEO Alvin Luk and CTO TJ Cradick explain how the company's Cas12 and 13 programs are different than Cas9, and they discuss the DMD presentation and how this program differs from the current microdystrophin product that is on the market. Plus, RNA editing programs targeting neovascular age-related macular degeneration and MECP2 Duplication Syndrome (MDS), and a DNA program targeting ALS.

en-us

00:10:42

ASGCT 2025: Dyno Therapeutics CEO Eric Kelsic...

BiotechTV - News ·

2025/05/15

He talks about new capsids Dyno announced at this years' conference and the science behind getting them to specific places in the body. Plus, the company's new 'Frontiers Program' and a Genetic Agency Technology Conference coming up in November.

en-us

00:17:24

ASGCT 2025: Physicians and scientists raced to make a...

BiotechTV - News ·

2025/05/15

As published in NEJM today, UPenn's Kiran Musunuru describes how the team used base editing in a matter of months to treat an infant with CPS1 deficiently, and his thoughts on what the learnings of this case are for drug development.

en-us

00:09:53

ASGCT 2025: Coave Therapeutics presented a late...

BiotechTV - News ·

2025/05/15

CEO Rodolphe Clerval walks us through Coave's "ALIGATER' ligand technology and describes the importance of the cerebrospinal administered program. Plus, comments on the company's IV program for CNS conditions, and a recent €32 million series A.

en-us

432 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter